AARD: Aardvark Therapeutics Inc. Book Value per Share

Symbol and logo of brand Aardvark Therapeutics Inc (AARD)

The market trend for Aardvark Therapeutics Inc (AARD), visualized in monetary terms, indicates volatility driven by the risk of trial failure and capital dilution from secondary offerings, with the metric currently at 3.41. Aardvark Therapeutics Inc (AARD) revenues will be based on the market launch of appetite suppressants and treatments for Prader-Willi syndrome. The current course is aimed at accelerating the final development stages of small molecules for the therapy of rare pathologies.

AARD Aardvark Therapeutics Inc. Share Book Value (02/14/2025 - 10/30/2026)

Summary analytical data breakdowns for aardvarktherapeutics.com (AARD)

- current quotes and average value forecast:
Price Chart Aardvark Therapeutics Corp|AARD - Fair Value Consensus
- market capitalization information:
Market Capitalization Aardvark Therapeutics Inc|AARD - Business Value
- business book valuation details:
Net Assets per Single Share Aardvark Therapeutics|AARD - Net Asset Value|Market Capitalization to Book Value Ratio aardvarktherapeutics.com|AARD - Aggregate Asset Value
- debt burden and liquidity indicators:
Total Debt to Capital Aardvark Therapeutics Inc|AARD - Long-Term Debt to Capital|Short-Term Debt to Equity Aardvark Therapeutics|AARD - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Aardvark Therapeutics Inc|AARD - Company Long-Term Liabilities|Company Short-Term Debts Aardvark Therapeutics|Quick Liquidity Indicator aardvarktherapeutics.com
- earnings and multiples data:
AARD - Final Profit
General company analysis:AARD - Aardvark Therapeutics Corp
Manufactured products of Aardvark Therapeutics

Aardvark Therapeutics Inc (AARD) development of innovative obesity pills requires significant capital expenditures, making the monitoring of net equity critical. Analyzing the book value per share allows for an assessment of real shareholder value net of liabilities, helping investors identify overpayment for the asset and avoid freezing funds by tracking equity adequacy trends on this chart.

Competitor analysis

ASND - Net Assets per Single Share|Accounting Value of a Share MDGL (Madrigal Corp)|CORT: Book Value per Share|Equity per Share RYTM|Net Assets per Single Share Akero|Metsera, Inc. - Share Book Value|Book Value per Share MLTX|CRNX (Crinetics Corp) - Accounting Value of a Share|Book Value per Share NAMS (NewAmsterdam Pharma)|Book Value per Share soleno.life SLNO|FOLD - Net Assets per Single Share|Accounting Value of a Share ETNB (89bio Inc)|Agios Pharmaceuticals Inc (AGIO) - Net Assets per Single Share|Accounting Value per Share Structure Corp|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com|Accounting Value per Share LXRX (Lexicon Pharmaceuticals, Inc.)|MBX (MBX Biosciences, Inc.) - Accounting Value of a Share|Net Assets per Single Share Altimmune Corp ALT|SGMT - Accounting Value per Share|BioAge Labs, Inc. - Book Value per Share|Net Asset Value per Share biomeafusion.com|QNCX (quincetx.com) - Accounting Value per Share|GUTS: Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share PLUR|Net Assets per Single Share SYBX (synlogictx.com)|Net Assets per Single Share Lipocine LPCN|Matinas BioPharma Holdings, Inc. (MTNB) - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO: Net Assets per Single Share|CTCX: Book Value per Share|LUMO - Net Assets per Share|Net Assets per Single Share Organovo|Radius Recycling Inc. (RDUS) - Net Assets per Share